Abstract

Human microbiota is a complex consortium of microorganisms involved in the proper functioning of almost every system of the organism. Majority of the human diseases are associated with the development of intestinal dysbiosis. Dysbiotic condition or dysbiosis is a key pathogenic condition causing many severe infectious or non-infectious diseases. Rapid return to the original microbiota in many cases leads to the fast recovery from the disease. However, the optimal way of the treatment of dysbiosis is still under the discussion. Recently we have developed a method of autoprobiotics based on using isolated indigenous bacteria for improving of microbiota condition. The method based on feeding the patients with bacterial products grown from their personal, genetically characterised strains have been successfully tested in clinic on patients with IBS or chronic pneumonia. In present study we tried to evaluate technology employing autoprobiotic bacteria belonging to different species employing the rat model of antibiotic induced dysbiosis. Six experimental groups of animals after taking antibiotics were treated with different variants of autoprobiotics (lactobacillus, bifidobacteria, enterococcus, their mixture, fecal microbiota, or anaerobically grown complex of indigenous microbiota) prepared for each of them before the development of dysbiosis. Judging by the multiple parameters including metagenomics analysis of microbiota, immune status and microbiota content of the animals with dysbiosis relatively to control group, the most pronounced positive changes were provided by autoprobiotics based on enterococci, bifidobacteria or the consortium of indigenous bacteria grown under anaerobic conditions. These groups of autoprobiotics were delivering the most effective restoration of the original microbiota content and significant anti-inflammatory reaction of the immune system.

Highlights

  • Human microbiota is a complex consortium of numerous species of bacteria, archaea, viruses, fungi, and protozoa

  • The general aim of the present work is to evaluate the therapeutic potential of different bacterial variants of autoprobiotics, employing an experimental model of antibiotic-induced dysbiosis followed by metagenome and immunological analysis

  • An autoprobiotic approach based on the use of personal bacterial strains was evaluated for the restoration of microbiota in a model of antibiotic-associated dysbiosis

Read more

Summary

Introduction

Human microbiota is a complex consortium of numerous species of bacteria, archaea, viruses, fungi, and protozoa (more than 500 bacterial species in the gut alone). It is considered as an additional organ in the human body (Suvorov, 2013). The application of Autoprobiotics Restore the Personal Microbiota next-generation sequencing (NGS) technology has increased the interest in the role of the microbiota in health and disease. This interest grew rapidly with the advent of several multinational scientific initiatives such as the NIH Human Microbiome Project (https://hmpdacc.org) and MetaHit Consortium (http:// www.metahit.eu). Gut microbiota being the most abundant microbial community in the organism is highly personal but generally favour a limited number of compositions known as enterotypes (Arumugam et al, 2011)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call